Lisia Maria Esper

Graduated in Biomedicine, has experience in the area of #8203;#8203;General Biology, with an emphasis on Cellular, Molecular Biology and Immunology, her main area of #8203;#8203;expertise. She worked as a researcher in the USA, acting as Research Assistant III at the Immunology Laboratory at Duke University and Medical Center (2004-2006) and at the Molecular Immunology Laboratory at Cincinnati Childrens Hospital Medical Center (2006-2008) respectively.It has Master's (2012) and Doctorate (2016) in Health Sciences from the Department of Clinical Medicine with an emphasis on Infectious Diseases and Tropical Medicine at the Medical School of Federal University of Minas Gerais.Post Doctorate in the Department of Biochemistry and Immunology, Federal University of Minas Gerais.Coordinator of the randomized, double-blind, placebo-controlled phase III clinical trial to assess the efficacy and safety of the Dengue 1, 2, 3, 4 (attenuated) vaccine at the Butantan Institute (DEN-03-IB) in Belo Horizonte.Lead Coordinator in the Project "A cluster-randomized trial to Evaluate the efficacy of Wolbachia-Infected Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil (Avoid Dengue) - DMID Protocol Number: 17-0111 (Source: Lattes Curriculum)